Tags

Type your tag names separated by a space and hit enter

Levodopa with benserazide or carbidopa in Parkinson disease.
Neurology. 1979 Dec; 29(12):1584-9.Neur

Abstract

Plasma levodopa and therapeutic responses to treatment with levodopa in combination with benserazide or carbidopa were studied in 49 patients with Parkinson disease not previously treated with levodopa in a blind randomized crossover trial. The treatment periods were 12 weeks; similar dosage schedules were used, with doses that induced equal levels of plasma levodopa in both combinations. In pretrial studies of plasma levodopa responses, 200 mg of levodopa and 50 mg of benserazide was equal to 250 mg of levodopa combined with 25 mg of carbidopa. Equal plasma levodopa responses to both combinations were also found during the trial. There was no significant difference between the treatment groups in beneficial effects on parkinsonian disability and individual symptoms or in the frequency of involuntary movements. However, nausea and vomiting occurred significantly more often during treatment with levodopa and carbidopa than during treatment with levodopa and benserazide. This difference was probably due to inadequate inhibition of peripheral decarboxylase inhibitor by the 1:10 ratio of carbidopa to levodopa.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

574221

Citation

Rinne, U K., and P Mölsä. "Levodopa With Benserazide or Carbidopa in Parkinson Disease." Neurology, vol. 29, no. 12, 1979, pp. 1584-9.
Rinne UK, Mölsä P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology. 1979;29(12):1584-9.
Rinne, U. K., & Mölsä, P. (1979). Levodopa with benserazide or carbidopa in Parkinson disease. Neurology, 29(12), 1584-9.
Rinne UK, Mölsä P. Levodopa With Benserazide or Carbidopa in Parkinson Disease. Neurology. 1979;29(12):1584-9. PubMed PMID: 574221.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levodopa with benserazide or carbidopa in Parkinson disease. AU - Rinne,U K, AU - Mölsä,P, PY - 1979/12/1/pubmed PY - 1979/12/1/medline PY - 1979/12/1/entrez SP - 1584 EP - 9 JF - Neurology JO - Neurology VL - 29 IS - 12 N2 - Plasma levodopa and therapeutic responses to treatment with levodopa in combination with benserazide or carbidopa were studied in 49 patients with Parkinson disease not previously treated with levodopa in a blind randomized crossover trial. The treatment periods were 12 weeks; similar dosage schedules were used, with doses that induced equal levels of plasma levodopa in both combinations. In pretrial studies of plasma levodopa responses, 200 mg of levodopa and 50 mg of benserazide was equal to 250 mg of levodopa combined with 25 mg of carbidopa. Equal plasma levodopa responses to both combinations were also found during the trial. There was no significant difference between the treatment groups in beneficial effects on parkinsonian disability and individual symptoms or in the frequency of involuntary movements. However, nausea and vomiting occurred significantly more often during treatment with levodopa and carbidopa than during treatment with levodopa and benserazide. This difference was probably due to inadequate inhibition of peripheral decarboxylase inhibitor by the 1:10 ratio of carbidopa to levodopa. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/574221/Levodopa_with_benserazide_or_carbidopa_in_Parkinson_disease_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=574221.ui DB - PRIME DP - Unbound Medicine ER -